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REVIEW CURRENTOPINION The natural history of HIV infectionCopyright © Lippincott W
1746-630X  2013 Wolters Kluwera bCaroline A. Sabin and Jens D. LundgrenPurpose of review
To review recent published literature around three areas: long-term nonprogression/viral control; predictors
of viral load set point/disease progression; and the potential impact of antiretroviral therapy (ART) in early
HIV infection.
Recent findings
The natural course of untreated HIV infection varies widely with some HIV-positive individuals able to
maintain high CD4 cell counts and/or suppressed viral load in the absence of ART. Although similar, the
underlying mechanistic processes leading to long-term nonprogression and viral control are likely to differ.
Concerted ongoing research efforts will hopefully identify host factors that are causally related to these
phenotypes, thus providing opportunities for the development of novel treatment or preventive strategies.
Although there is increasing evidence that initiation of ART during primary infection may prevent the
immunological deterioration which would otherwise be seen in untreated HIV infection, recent studies
do not address the longer term clinical benefits of ART at this very early stage.
Summary
A better understanding of the relative influences of viral, host, and environmental factors on the natural course
of HIV infection has the potential to identify novel targets for intervention to prevent and treat HIV-infected
persons.
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In the early days of the HIV epidemic, knowledge
about the natural history of HIV accrued rapidly.
However, the widespread use of effective antiretro-
viral therapy (ART) brought a shift in focus of the
research community away from studies of natural
history to those of treated infection. Nevertheless,
recent years have seen many advances in our know-
ledge about natural history. For the purposes of this
review, we will focus on three areas of relevance to
treating clinicians: long-term nonprogression and
viral control; predictors of viral load set point and
disease progression; and the potential impact of ART
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ELITE CONTROLLERS
The natural course of untreated HIV infection varies
widely. The past decade has seen considerable inter-
est in the identification of subgroups of HIV-positive
persons who exhibit distinct patterns of disease
progression. It is hoped that the information
obtained through the identification of suchilliams & Wilkins. Unau
Health | Lippincott Williams & Wilkiindividuals might provide insight for the develop-
ment of vaccines and novel treatment approaches.
Long-term nonprogressors (LTNP) are individ-
uals who remain asymptomatic for a prolonged
period of time off ART with a high CD4 cell count
(see reviews by Poropatich and Sullivan and
Gaardbo et al. [1,2
&
]). Although it is widely reported
that 1–5% of the HIV-positive population are LTNP,
these estimates are complicated by the fact that
there is no standardized definition of a LTNP, andthorized reproduction of this article is prohibited.
ns www.co-hivandaids.com
CKEY POINTS
 Despite the existence of several phenotypes associated
with slowly progressing HIV infection, it is likely that
virtually all HIV-positive individuals will eventually
experience disease progression if left untreated.
 Variation in viral characteristics, host defence responses
(likely explained by variation in host genetics), and
environmental factors may all contribute to the variation
in the natural course of HIV infection.
 If concerted research efforts are able to identify host
factors that are causally related to viral control, this will
provide insight for the development of therapeutic or
preventive intervention strategies.
 Further evidence has accrued that initiation of ART
during primary infection may prevent the
immunological deterioration that is the hallmark of
untreated HIV infection, although the longer term
clinical benefits of such an approach remain unclear.
 Although there is global consensus of the benefits of
initiating ART during chronic infection in those with HIV-
related symptoms and/or a low CD4 cell count, such a
consensus has not yet been reached for the initiation of
ART in asymptomatic individuals with a CD4 cell count
more than 350 cells/ml.
Thirty years of HIV and AIDSthus definitions used (and the way in which they
are applied, particularly in the presence of varying
follow-up and irregularlymeasured CD4 cell counts)
differ widely (Table 1) [3–5,6
&&
,7,8]. For example,
Madec et al. [3] identified asymptomatic individuals
who remained off ART for more than 8 years with
a CD4 cell count more than 500 cells/ml; using
this definition, 9% of their clinic population were
identified as LTNP. Using a similar definition but
with only 7 years of follow-up, Okulicz et al. [4]
reported a prevalence of 5.02% in a military cohort.
In contrast, only 0.4% of patients in the French
Hospital’s Database on HIV were identified as LTNP
[5]. In a UK study, Mandalia et al. [6
&&
] identified
ART-naive asymptomatic individuals infected with
HIV for more than 7 years. Of 312 such patients,
only 50 had stable CD4 cell counts, with only
13 having CD4 cell counts consistently in the
normal range. Thus, LTNP represented only 0.2%
of patients attending for care, a far lower rate than
that reported by Okulicz et al., presumably because
of the additional requirement that individuals had
stable CD4 cell counts.
LTNP status can be lost, and thus the reported
prevalence of LTNP within a study will depend on
the required period of follow-up. In Madec’s study
[3], LTNP status was lost after 8 years in 36 of the
60 LTNP; loss of LTNP status was generally becauseopyright © Lippincott Williams & Wilkins. Unautho
312 www.co-hivandaids.comof declining CD4 cell counts and initiation of ART,
although a small number of individuals experienced
Centers for Disease Control stage B/C disease.
Predictors of loss of LTNP status were a high baseline
HIV DNA level and a more rapid increase in HIV
DNA over the first years of follow-up, suggesting
the presence of ongoing (but low-grade) viral repli-
cation. Indeed, HIV RNA levels in plasma increased
by 0.04 log10 copies/ml per year over the first 8 years
after diagnosis. When the required period of follow-
up was increased from 7 to 10 years in a military
cohort [4], the prevalence of LTNP status dropped
from 5 to 2%. The fact that an individual’s LTNP
status can change has led some to suggest that rather
than representing a distinct group of HIV-positive
individuals, LTNP are more likely to represent
individuals at one tail end of a Normal distribution
[6
&&
]. As such, it is likely that virtually all HIV-
positive persons will eventually experience disease
progression if left untreated.
More recently, interest has shifted towards
the identification of individuals who are able to
suppress HIV replication to such an extent that viral
load levels remain undetectable in the absence of
ART [9]. These individuals are generally referred
to as elite controllers or viral controllers. In the
military cohort described by Okulicz et al. [4] elite
controllers were defined as ART-naive patients
infected with HIV for more than 12 months with
at least three longitudinal undetectable HIV RNA
determinations. Individuals were allowed to have
occasional HIV RNA levels up to 1000 copies/ml as
long as these episodes represented the minority
of all determinations. These elite controllers were
distinguished from viremic controllers in whom
the majority of viral loads were in the range
1000–2000 copies/ml. In total, 0.6% of 4586 indi-
viduals were identified as elite controllers and
3.3% as viremic controllers. Virological control
was established a median of 1 year after seroconver-
sion, lasted for 846 and 1085 days in elite controllers
and viremic controllers, respectively, and was asso-
ciated with a reduced risk of clinical progression.
Interestingly, although elite controllers experienced
an initial CD4 cell count increase followed by
stabilization, viremic controllers generally experi-
enced a loss of CD4 cells. Goujard et al. [10]
confirmed that elite controllers status is established
early after primary infection in the Agence Nationale
de Recherche sur le Sida PRIMO cohort.
Although there is clearly overlap between
the LTNP and elite controller groups, not all LTNP
have a suppressed viral load, and not all elite
controllers have high CD4 cell counts. Furthermore,
LTNP status is not necessarily protective against
clinical progression. An early study from therized reproduction of this article is prohibited.
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1746-630X  2013 Wolters Kluwer Health | Lippincott Williams & WilkiCASCADE group [11] suggested that 15 and 7% of
elite controllers infected with HIV for more than
16 years had CD4 cell counts less than 350 cells/ml or
AIDS, respectively. A more recent study from the
group [12] demonstrated that the proportion of elite
controllers with at least one CD4 cell count less than
500 cells/ml ranged from 45 to 53%, depending
on the definition of elite controllers. Sedaghat
et al. [13] noted that CD4 slopes in elite controllers
varied substantially with rates of CD4 loss of up to
53 cells/ml per year in some individuals. Using a
highly sensitive viral load assay, Pereyra et al. [14]
reported that the median viral load was 2 copies/ml
in 90 elite controllers. Low-level viremia was present
in the majority of elite controllers; CD4 loss was
more common among those with low-level viremia
than in those without detectable virus. Boufassa
et al. [15] reported that clinical and immunological
progression in elite controllers was restricted to
those experiencing viral load ‘blips’.
More recently, Groves et al. [16
&&
] identified
ART-naive patients who had maintained a viral load
less than 2000 copies/ml for more than 12 months.
Typical controllers had an average recent CD4 cell
count more than 450 cells/ml (2.1% of population),
whereas discord controllers had an average recent
CD4 cell count less than 450 cells/ml (0.6%). Thus,
in this study, the term discord controller was used
to identify individuals who had experienced a loss
of CD4 cells despite viral control. There were no
significant differences in viral load or demographic
factors between the two groups. Interestingly, there
was a suggestion of a higher frequency of infection
with subtype C virus in discord controllers (40%
of patients) compared with the entire clinic popu-
lation of whom25.1%were infected with subtype C;
whether this overrepresentation relates to specific
features of subtype C virus itself, or whether subtype
C is merely a marker of infection in certain regions
of the world with specific host genetic and environ-
mental factors is, however, unclear.
As with LTNP, several studies have attempted
to identify factors associated with elite controller
status. Yang et al. [17] considered the relative and
absolute numbers of naive T-cells in a cohort of
elite controllers with normal or declining CD4 cell
counts and in ART-treated individuals. The relative
proportions of naive CD4 and CD8 T cells were
reduced in elite controllers, resembling the patterns
seen in individuals with untreated progressive HIV
infection. The authors concluded that loss of naive
CD4 T cells is a universal feature of elite controllers,
despite the ability of such individuals to maintain
undetectable viral loads. Chen et al. [18] suggested,
based on in-vitro experimentation, that CD4
naive lymphocytes from elite controllers were lessthorized reproduction of this article is prohibited.
ns www.co-hivandaids.com 313
CThirty years of HIV and AIDSsusceptible to HIV infection than such lymphocytes
from progressors or uninfected individuals. This
specific feature was linked with upregulation of a
cellular kinase (p21). Mahnke et al. [19
&
] compared
patients maintaining low levels of viremia (control-
lers) with those experiencing disease progression
within 2 years of diagnosis (fast progressors) and
with progressive disease not requiring ART (slow
progressors). Although beneficial human leukocyte
antigen (HLA) types (HLA-B27, B57, and B58)
were seenmore commonly in controllers (57%) they
were also expressed by 23% of slow progressors.
Progressors were more likely to be coinfected with
GB virus C than controllers, coinfection with which
has previously been reported by some to be associ-
ated with a slower rate of disease progression in HIV
infection [20], but the CCR5 D32 mutation was sim-
ilarly distributed across the groups. Plasma HIV viral
load did not differ between progressors, but cell-
associated viral load was elevated in fast progressors
and lowered in controllers. Although the frequency
of CD38þCD8þ T cells was a strong predictor of
disease progression in the first year after HIV infec-
tion, and was sufficient to distinguish progressors
from controllers, this measurement alone could
not differentiate between fast and slow progressors.
As the two groups of individuals appear to
be clinically distinct, suggesting differences in the
processes that lead to long-termnonprogression and
elite control, several research groups have attempted
to investigate whether there are any demographic
or biological differences between these two patientopyright © Lippincott Williams & Wilkins. Unautho
Mechanism
Viral factors (attenuated virus)
  Deletion of key regulatory gene
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FIGURE 1. Potential mechanisms of viral suppression in HIV cont
314 www.co-hivandaids.comgroups [4]. Groves et al. [16
&&
] reported a more
marked depletion of the naive T-cell subset in
discord controllers than in typical controllers but
a trend towards increased activated effectormemory
CD4 cells in typical controllers. CD8 T-cell acti-
vation was increased to a similar level (compared
with noncontrollers) in both controller groups.
The authors concluded that despite the lower CD4
cell counts in discord controllers, their CD8 T-cell
activation pattern more closely resembled that
of typical controllers. As with other studies, the
discord controllers had higher viral DNA loads than
the typical controllers, suggesting continued viral
replication in this subgroup.
Shaw et al. [21] compared viral controllers (indi-
viduals with viral load<1000copies/ml for>5 years)
to viremic slow progressors (individuals with a viral
load >10000copies/ml but who had maintained
a CD4 cell count >500cells/ml for >7 years) and
viremic progressors (individuals infected for a similar
time with viral load >10000copies/ml but CD4 cell
count <500cells/ml). Viremic slow progressors had
higher levels of markers of mucosal immune acti-
vationand lownumbers ofmucosal Tregs, suggesting
that factors other than immune activation account
for this phenotype. Gaardbo et al. [7] reported that
LTNP had a higher frequency of activated CD4 and
CD8cells comparedwithviral controllers, but similar
levels to progressors. Ballana et al. [8] confirmed
results from other studies [22] showing that a single
nucleotide polymorphism 35kb upstream of the
HLA-C gene (35C/T) is associatedwith LTNP status.rized reproduction of this article is prohibited.
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The natural history of HIV infection Sabin and LundgrenHIV-specific CD4 activation is a hallmark of viral
control [23] but, as outlined above and reviewed
recently [24] (see Fig. 1), many other host factors
have been linked with this phenotype, including
cellular restriction factors such as APOBEC, tetherin,
and the recently identified SAMHD1 [25,26].
In addition, several viral factors may also play a role,
including deletions or mutations with the viral
genes [27] that may have an impact on the ability
of the virus to replicate. Concerted ongoing research
efforts will hopefully clarify whether any of these
host factors are causally related to viral control or
merely reflect intrinsic variations in the ability of
the virus to replicate. If any host or viral factors do
have an important influence on viral replication,
such a discovery will open a field of possibilities
aimed at enhancing or mimicking these host
factors as part of a therapeutic or preventive inter-
vention strategy.OTHER PREDICTORS OF VIRAL LOAD SET
POINT AND CD4 LOSS
The possibility that there may be a link between the
viral load set point and the viral load of the infecting
partner was raised by Hecht et al. [28] who demon-
strated that in 24 transmission pairs, the viral load
in the donor was closely associated with the viral
load at presentation in the seroconverting partner
(correlation coefficient¼0.55). Using a novel
phylogenetic approach to determine heritability,
Alizon et al. [29] concluded that up to half the
variance in the viral load set point among indi-
viduals in the Swiss HIV Cohort Study could be
heritable from their infecting partners. These obser-
vations support the notion that HIV has varying
intrinsic replicative capacity and suggest that this
feature is maintained after transmission.
Predictors of the viral load set point were
investigated by Lingappa et al. [30
&&
] in 141 African
seroconverters. In multivariable analysis, higher
viral loads in the source partners were associated
with higher viral load set points in the seroconvert-
ers. The proportion of variation in set point that
could be attributed to the viral load of the source
partner, after controlling for other factors, was 6%.
Despite this low proportion, the authors concluded
that the source partner viral load was the most
significant predictor of the viral load set point in
the seroconverter. Yue et al. [31
&&
] also noted
the relatively small proportion of variance in the
viral load set point that could be explained by the
viral load in the source partner. In an analysis of
195 transmission pairs from Zambia, the viral load
in source partners explained only around 2% of the
variance in viral load set points of seroconverters.Copyright © Lippincott Williams & Wilkins. Unau
1746-630X  2013 Wolters Kluwer Health | Lippincott Williams & WilkiOverall, the viral load set point was a function of
the source partner viral load, the sex of the
seroconverter, the HLA class I alleles of the sero-
converter, and the sharing of HLA-I alleles between
partners in a transmission pair. Together, these
factors accounted for up to 37% of variance in the
viral load set point. Roberts et al. [32] reported
that the concentration of five plasma cytokines
(IL-12p40, IL-12p70, IFN-g, IL-7, and IL-15) pre-
dicted 66% of the variation in viral load set point
in 40 South African women. Grinsztejn et al. [33
&
]
reported that women in the Prospective Evaluation
of Antiretrovirals in Resource-Limited Settings
(PEARLS) study had a lower mean preART viral load
than men; whereas the sex difference was related to
the CD4 cell count, it was independent of country
and persisted in those with a CD4 cell count less
than 200 cells/ml.
Other predictors of disease progression include
transmission of resistant strains of HIV [34] and the
envelope diversity of the virus in the individual
after seroconversion [35
&
]. In the latter study, viral
diversity at 1-year postseroconversion was associ-
ated with accelerated progression to clinical AIDS
or a low CD4 cell count, although not with the
viral load set point itself. The authors could not
determine whether viral diversity is a direct cause
of immunodeficiency, or a consequence of the
individual’s response to infection. In a small study
of 50, chronically infected, asymptomatic, ART-
naive adults from the United Kingdom and China
[36], the antiviral inhibitory capacity of CD8þ T cells
was highly predictive of CD4 cell loss in early HIV
infection. Audige et al. [37] reported that fast pro-
gressors (those with a CD4 cell count <200 cells/ml
within 7.5 years) had significantly lower postsero-
conversion CD4 cell counts than either intermedi-
ate (7.5–12 years) or slow (>12 years) progressors;
fast progressors had cell-surface CD4 densities that
decreased more rapidly than slow progressors.ANTIRETROVIRAL THERAPY DURING
PRIMARY HIV INFECTION
There is global consensus that there is a favourable
benefit : risk ratio for initiating ART in those with
HIV-related symptoms or with a CD4 cell count less
than 350 cells/ml. Because of the risk of disease
progression in these individuals, the benefits of
ART outweigh any potential risks of adverse drug
reactions. Such a favourable benefit : risk ratio has
not yet been established for initiating ART earlier in
the course of infection in asymptomatic individuals.
Several recent publications provide further evi-
dence that initiation of ART during primary infec-
tion may prevent the immunological deterioration,thorized reproduction of this article is prohibited.
ns www.co-hivandaids.com 315
CThirty years of HIV and AIDSwhich would otherwise be seen in untreated HIV
infection. In one observational study, 64% of indi-
viduals who initiated ART during primary infection
maintained a CD4 cell count more than 900cells/ml
compared with only 34% of those who deferred ART
to a later time [38
&
]. In the Short Pulse Anti Retroviral
Therapy at HIV Seroconversion (SPARTAC) trial,
366 adults with primary infection were randomized
to receive either short-term (12weeks) or longer term
(48 weeks) immediate ART, or to defer ART until the
CD4 cell count dropped to less than 350cells/ml
[39
&&
]. Immediate use of ART reduced the chance of
experiencing a CD4 cell count less than 350cells/ml
while the patient remained on ART, but not beyond
theduration of treatment.Using data from the obser-
vational CASCADE collaboration, Zugna et al. [40
&
]
reported that although individuals initiating treat-
mentwithin 12months of seroconversionweremore
likely to interrupt therapy than those initiating treat-
ment during chronic infection, rates of virological
failure and treatment change were similar between
the two groups.
Although these studies demonstrate that ART
can prevent the deterioration of the immune system
which would otherwise be seen without treatment,
they do not address whether those initiating ART
during primary infection experience any long-term
clinical benefit (in terms of reduced morbidity or
mortality) from this treatment, and thus whether
allowing CD4 cell counts to fall to lower levels will
result in any appreciable negative consequences
over either the shortterm or longterm. Unfortu-
nately, such information can only be obtained
from clinical endpoint studies with the requirement
for substantially larger sample sizes. The ongoing
Strategic Timing of Anti-Retroviral Treatment
(START) study [41] aims to address this question.CONCLUSION
Although the clinical, immunological, and virolog-
ical course of untreated HIV infection is variable,
few persons followed for more than 8–10 years
remain without any evidence of disease progression.
Variation in viral characteristics, host defence
responses (likely explained by variation in host
genetics), and environmental factors may all con-
tribute to the variation in the natural course of
HIV infection. A better understanding of the relative
influence of these factors is emerging. This line of
research has the potential to identify novel targets
for intervention to prevent and treat HIV-infected
persons.
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